Approval for the addition of the afp assay on the architect immunoassay instrument.  The device, as modified, will be marketed under the trade name architect afp assay and is indicated for the quantitative determination of alpha-fetoprotein (afp) in : 1) human serum or plasma to aid in the management of patients with nonseminomatosus testicular cancer.  2) human serum, plasma, and amniotic fluid at 15 to 21 weeks gestation to aid in the detection of fetal open neural tube defects (ntd).